What is Retatrutide and How Does It Work?
Retatrutide is an investigational anti-diabetic and chronic weight-management medication developed by Eli Lilly. Unlike previous generations of GLP-1 medications, Retatrutide is highly unique because it is a triple-hormone receptor agonist. It simultaneously targets three key metabolic receptors:
- GLP-1 (Glucagon-like peptide-1): Slows gastric emptying and stimulates insulin secretion.
- GIP (Glucose-dependent insulinotropic polypeptide): Works synergistically with GLP-1 to suppress appetite and improve insulin sensitivity.
- Glucagon Receptor: Increases energy expenditure (calorie burning) and rapidly clears fat from the liver.
Clinical Reconstitution Math
In clinical research, lyophilized (freeze-dried) Retatrutide must be reconstituted with Bacteriostatic Water before administration. Because the standard titration protocol is highly specific (starting at 2mg per week and increasing slowly to mitigate nausea), accurate volumetric math is required.
A Practical Example
Consider a researcher with a 12mg vial of Retatrutide. They add 2mL of Bacteriostatic Water to the vial. Their desired starting dose is 2mg.
Step 1: 12mg ÷ 2mL = 6mg per mL.
Step 2: (2mg ÷ 6mg/mL) × 100 = 33.3 Units.
The researcher would draw the U-100 syringe to approximately the "33" tick mark to administer exactly 2mg.